Northwestern University at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Northwestern University takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on a phase 2a trial of neflamapimod, an oral p38 alpha kinase inhibitor, in non-fluent variant primary progressive aphasia, including its neurodegeneration biomarker results.

OrganizationCTAD 2026 Attendance
Northwestern University
Evanston, Illinois
northwestern.edu
Universities & institutes
Its Chicago medical campus hosts an NIA-funded Alzheimer's Disease Research Center known for SuperAging and primary progressive aphasia studies.
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Northwestern University

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction